진바이오텍
Financials
Valuation Metrics
진바이오텍's Market Cap is ₩429B. At end of 2025 it was ₩345B. Ranked #1812 of 2,405 in KR market (top 75%), #1113 of 1,627 on KOSDAQ (top 68%), #193 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 84%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 42.88B KRW | KR#1,812/2,405 Sec#193/231 |
| Revenue | 89.31B KRW | KR#1,480/2,405 Sec#92/231 |
| Net Income | 3.67B KRW | KR#1,307/2,405 Sec#91/231 |
| Total Assets | 80.28B KRW | KR#1,929/2,405 Sec#160/231 |
| Net Assets | 56.25B KRW | KR#1,823/2,405 Sec#153/231 |
| Employees | 43 | KR#2,098/2,405 Sec#193/231 |
| Value | ||
| P/E | 11.68x | KR#953/2,405 Sec#51/231 |
| P/B | 0.76x | KR#1,282/2,405 Sec#76/231 |
| PEG | 5.70x | KR#816/2,405 Sec#52/231 |
| P/S | 0.48x | KR#938/2,405 Sec#44/231 |
| EV/EBITDA | 11.21x | KR#715/2,405 Sec#37/231 |
| FCF Yield | 8.99% | KR#678/2,405 Sec#30/231 |
| Profitability | ||
| ROE | 6.53% | KR#933/2,405 Sec#64/231 |
| ROA | 4.57% | KR#786/2,405 Sec#62/231 |
| Op. Margin | 5.08% | KR#951/2,405 Sec#71/231 |
| Revenue Growth | 0.97% | KR#1,455/2,405 Sec#144/231 |
| Earnings Growth | 2.05% | KR#815/2,405 Sec#52/231 |
| Financial Health | ||
| Debt Ratio | 42.70% | KR#846/2,405 Sec#99/231 |
| Total Debt | 17.20B KRW | KR#1,428/2,405 Sec#118/231 |
| FCF | 3.86B KRW | KR#965/2,405 Sec#69/231 |
| Cash | 9.23B KRW | KR#1,733/2,405 Sec#151/231 |
| Current Ratio | 3.13x | KR#524/2,405 Sec#74/231 |
| Net Debt/EBITDA | 1.76x | KR#812/2,405 Sec#58/231 |
| Dividend | ||
| Div. Yield | 1.00% | KR#1,139/2,405 Sec#65/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | 26.08% | KR#275/2,405 Sec#15/231 |
| 1M Return | -0.30% | KR#345/2,405 Sec#38/231 |
| From 52W High | -16.86% | KR#138/2,405 Sec#5/231 |
| 1Y MDD | -28.68% | KR#198/2,405 Sec#12/231 |
| Trading | ||
| Volume | 9,378 shares | KR#1,865/2,405 Sec#187/231 |
| Trading Value | 46.8M KRW | KR#1,760/2,405 Sec#187/231 |
| Foreign Own. | 2.52% | KR#1,445/2,405 Sec#136/231 |
| Per Share | ||
| EPS | 426 KRW | KR#1,053/2,405 Sec#74/231 |
| BPS | 6,533 KRW | KR#1,306/2,405 Sec#92/231 |
Company Info
Jin Biotek, established in 2000 and headquartered in Gongju-si, Chungcheongnam-do, was founded to manufacture and sell functional feed additives using beneficial microorganisms, listing on KOSDAQ in 2006. In 2011, it acquired Dawon Chemical Co., Ltd., an animal pharmaceutical company, and supplies natural, eco-friendly feed ingredients and additives based on solid-state fermentation technology. The company focuses on developing technologies and products for environmental improvement, greenhouse gas reduction, and pet food, snacks, and supplements, driven by future technology R&D and ESG management.